Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey

Overview

Journal Low Urin Tract Symptoms

Specialties Pathology
Urology

Date 2024 Nov 5

PMID 39497630

Authors

Shoko Yoshimura

Hiromitsu Yagi

Kazunori Abe

Masakazu Yamasaki

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the safety and effectiveness of vibegron, a highly selective β-adrenoceptor agonist, in Japanese patients with overactive bladder (OAB) in a real-world clinical setting.

Methods: This prospective survey was conducted from August 2019 to July 2023 using a central registration method. Patients newly treated with vibegron for OAB were followed for 12 weeks, and those who continued treatment were observed for up to 52 weeks. Adverse drug reactions (ADRs) and the overall improvement level were assessed, and overactive bladder symptom score (OABSS) and International Prostate Symptom Score-Quality of Life (IPSS QOL) score were collected.

Results: Of the 1848 patients in the safety analysis set, 154 ADRs were reported in 141 patients (7.63%). Common ADRs were increased residual urine volume (1.30%), constipation (1.14%), dysuria and urinary retention (0.97% each), cystitis (0.65%), and dry mouth (0.32%). The incidence of urinary retention-related adverse events (AEs) was higher in male patients, patients ≥ 65 years old, and patients with benign prostatic hyperplasia. The effectiveness rate was 88.8% among the 1561 patients in the effectiveness analysis set. Significant improvement in both OABSS and IPSS QOL scores was observed at all observation periods. The rate of achieving the minimal clinically important change in OABSS total score at the final evaluation was 75.35%. OABSS scores were also significantly reduced in all subgroup analyses.

Conclusions: This survey found no major concerns regarding the safety and effectiveness of vibegron in Japanese OAB patients, except for urinary retention-related AEs. Vibegron is considered to represent a useful drug for treating OAB symptoms in a real-world clinical setting.

References

Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S . Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020; 125(5):709-717. PMC: 7318146. DOI: 10.1111/bju.15020. View

Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd Jr P . International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol. 2020; 204(2):316-324. DOI: 10.1097/JU.0000000000000807. View

Homma Y, Yamaguchi O, Hayashi K . An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005; 96(9):1314-8. DOI: 10.1111/j.1464-410X.2005.05835.x. View

Gotoh M, Homma Y, Yokoyama O, Nishizawa O . Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology. 2011; 78(4):768-73. DOI: 10.1016/j.urology.2011.06.020. View

Fujimura T, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y . Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol. 1999; 161(2):680-5. View

Sexton C, Notte S, Maroulis C, Dmochowski R, Cardozo L, Subramanian D . Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011; 65(5):567-85. DOI: 10.1111/j.1742-1241.2010.02626.x. View

Serlin D, Heidelbaugh J, Stoffel J . Urinary Retention in Adults: Evaluation and Initial Management. Am Fam Physician. 2018; 98(8):496-503. View

Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T . Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. PLoS One. 2023; 18(9):e0290685. PMC: 10473532. DOI: 10.1371/journal.pone.0290685. View

Brucker B, King J, Mudd Jr P, McHale K . Selectivity and Maximum Response of Vibegron and Mirabegron for β-Adrenergic Receptors. Curr Ther Res Clin Exp. 2022; 96:100674. PMC: 9184556. DOI: 10.1016/j.curtheres.2022.100674. View

10.

Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S . Efficacy of novel β -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. Int J Urol. 2018; 26(3):369-375. PMC: 6912249. DOI: 10.1111/iju.13877. View

11.

Kato D, Uno S, Van Schyndle J, Fan A, Kimura T . Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. Int J Urol. 2017; 24(10):757-764. DOI: 10.1111/iju.13422. View

12.

Tachikawa K, Kyoda Y, Fukuta F, Kobayashi K, Masumori N . Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01. Low Urin Tract Symptoms. 2021; 14(2):109-116. DOI: 10.1111/luts.12417. View

13.

Kuno T, Tamura K, Shimizu N, Fukuhara H, Fukata S, Ashida S . Vibegron 50 mg Once Daily Improves OABSS, OAB-q SF Score in OAB Patients ≥80 Years Old in Real-World Clinical Settings and Switching from Other OAB Drugs May Reduce Residual Urine Volume. Res Rep Urol. 2023; 15:157-164. PMC: 10216872. DOI: 10.2147/RRU.S411841. View

14.

Nozawa Y, Kato D, Tabuchi H, Kuroishi K . Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study. Low Urin Tract Symptoms. 2016; 10(2):122-130. DOI: 10.1111/luts.12148. View

15.

Coyne K, Sexton C, Kopp Z, Ebel-Bitoun C, Milsom I, Chapple C . The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011; 108(9):1459-71. DOI: 10.1111/j.1464-410X.2010.10013.x. View

16.

Maeda K, Katashima R, Ishizawa K, Yanagawa H . Japanese Physicians' Views on Drug Post-Marketing Surveillance. J Clin Med Res. 2015; 7(12):956-60. PMC: 4625816. DOI: 10.14740/jocmr2328w. View

17.

Eapen R, Radomski S . Review of the epidemiology of overactive bladder. Res Rep Urol. 2016; 8:71-6. PMC: 4902138. DOI: 10.2147/RRU.S102441. View

18.

He W, Zhang Y, Huang G, Tian Y, Sun Q, Liu X . Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. Low Urin Tract Symptoms. 2023; 15(3):80-88. DOI: 10.1111/luts.12475. View

19.

Kondo H, Masamune K . Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan. Ther Adv Drug Saf. 2022; 12:20420986211065215. PMC: 8689626. DOI: 10.1177/20420986211065215. View

20.

Kennelly M, Wielage R, Shortino D, Thomas E, Mudd Jr P . Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. 2022; 11. PMC: 9576010. DOI: 10.7573/dic.2022-4-2. View